Bayer claims full rights to Vitrakvi from Lilly’s Loxo

Eli Lilly and Co. (NYSE:LLY) gained two fewer assets from its acquisition of Loxo Oncology Inc. than planned, as Loxo partner Bayer AG (Xetra:BAYN) said Feb. 15 it will exercise a change-of-control

Read the full 328 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE